To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:8 Number:17 ISSN#:2564-2537
ACE Report #9350
Ace Report Cover Metabolic Disorders

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

How to Cite

OrthoEvidence. Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis. ACE Report. 2017;6(8):17. Available from:

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

Contributing Authors:
S Ferrari C Libanati JD Adachi E Czerwinski EM Lewiecki A Grauer F Cosman L Chen N Binkley E Lau DB Crittenden J Maddox CA Zerbini LC Hofbauer A Miyauchi CE Milmont PD Meisner

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


7180 postmenopausal women with osteoporosis were randomized to 12 months of treatment with either romosozumab or placebo, followed by a further 12 months of treatment with denosumab in both groups. The purpose of this study was to evaluate and compare vertebral fracture incidence, nonovertebral fracture incidence, and safety outcomes between groups after 6, 12, 18, and 24 months. Results after 12 ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.